Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets

 Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets

Shots:

  • The companies collaborated for Adagio’s ADG20 for both the treatment & prevention of COVID-19 as monothx. or combination regimen
  • Biocon will gain rights to manufacture & commercialize ADG20 for COVID-19 in India and select emerging markets based on the commercial process developed for ADG20. The company will have the access to Adagio’s ongoing P-II/III study data & to its anticipated EUA along with regulatory submissions, supporting the approval or EUA in India & other emerging markets
  • ADG20 is currently being evaluated in two studies. The STAMP trial to evaluate ADG20 for non-hospitalized COVID-19 patients and the EVADE trial to evaluate ADG20 for the prevention of COVID-19

Click here to­ read full press release/ article | Ref: Businesswire | Image: Adagio

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post